Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Henlius partners with Sandoz to develop up to 10 biosimilars targeting $100.5 million revenue by 2026.

Aug 17, 2026•about 8 hours ago

Contract Type

partnership

ShanghaiManufacturingBiotechnologyBiopharma

Description

Henlius has formed a strategic partnership with Sandoz to collaborate on the global development and commercialization of up to 10 biosimilar products. This partnership builds on prior oncology biosimilars agreements and includes substantial payments, with expected revenue of $100.5 million in 2026.

Company Information

Company

Shanghai Henlius Biotech and Organon

Location

Shanghai, China

About

Shanghai Henlius Biotech, Inc. is a global biopharmaceutical company focused on providing high-quality, affordable, and innovative biologics to patients worldwide. Established in 2010, it has launched several products in China and has products approved for international markets. The company's expertise spans R&D, manufacturing, and marketing with a strong emphasis on oncology, autoimmune diseases, and ophthalmology. Henlius is committed to developing a diverse portfolio of products covering over 50 molecules.

Predictive Intelligence
Strategic

ML-powered predictions for Shanghai Henlius Biotech and Organon's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.